GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Study to Assess the Safety & Reactogenicity of GSK Biologicals' DTPa/Hib Vaccine When Given at 3, 4 and 5 Months of Age

Phase 3

Completed

Conditions: Tetanus
Diphtheria
Haemophilus Influenzae Type b
Acellular Pertussis

First Posted Date: 2006-09-25

Last Posted Date: 2016-10-12

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 30

Registration Number: NCT00379977

Locations: 🇨🇳
GSK Investigational Site, Nanning, Guangxi, China

RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Rosiglitazone
Drug: Sulfonylurea
Drug: Metformin

First Posted Date: 2006-09-22

Last Posted Date: 2017-03-23

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 4447

Registration Number: NCT00379769

Locations: 🇬🇧
GSK Investigational Site, Worle, Weston-Super-Mare, United Kingdom

The Anti-Inflammatory And Metabolic Effects Of Rosiglitazone In Subjects With Rheumatoid Arthritis

Phase 2

Completed

Conditions: Arthritis, Rheumatoid

First Posted Date: 2006-09-22

Last Posted Date: 2016-10-26

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 96

Registration Number: NCT00379600

Locations: 🇬🇧
GSK Investigational Site, Glasgow, Lanarkshire, United Kingdom

Prednisolone Novel Endpoint Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Phase 1

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

First Posted Date: 2006-09-22

Last Posted Date: 2017-07-11

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 90

Registration Number: NCT00379730

Locations: 🇿🇦
GSK Investigational Site, Mowbray, South Africa

A Study Evaluating Vardenafil Compared to Placebo in Subjects With Erectile Dysfunction (ED) and Dyslipidemia

Phase 4

Completed

Conditions: Erectile Dysfunction

Interventions: Drug: placebo
Drug: LEVITRA (vardenafil)

First Posted Date: 2006-09-22

Last Posted Date: 2017-08-16

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 395

Registration Number: NCT00379756

Locations: 🇺🇸
GSK Investigational Site, Milwaukee, Wisconsin, United States

Trial With Rhinitic Patients Taking GSK256066 Versus Placebo In A Pollen Challenge Chamber

Phase 2

Completed

Conditions: Rhinitis, Allergic, Seasonal
Seasonal Allergic Rhinitis

First Posted Date: 2006-09-18

Last Posted Date: 2015-04-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 44

Registration Number: NCT00377728

Locations: 🇦🇹
GSK Investigational Site, Vienna, Austria

Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™

Phase 4

Completed

Conditions: Influenza

Interventions: Biological: Fluarix™

First Posted Date: 2006-09-18

Last Posted Date: 2018-10-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 3054

Registration Number: NCT00377611

Locations: 🇵🇱
GSK Investigational Site, Wroclaw, Poland

Demonstrate the Superiority of the Immune Response of Adjuvanted Influenza Vaccine Induced in an Adult Population

Phase 2

Completed

Conditions: Influenza

First Posted Date: 2006-09-18

Last Posted Date: 2017-04-24

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 3350

Registration Number: NCT00377585

Locations: 🇳🇴
GSK Investigational Site, Skien, Norway

Safety And Tolerability Study In Patients With Chronic Obstructive Pulmonary Disease

Phase 2

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

First Posted Date: 2006-09-15

Last Posted Date: 2018-06-07

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 45

Registration Number: NCT00376714

Locations: 🇸🇪
GSK Investigational Site, Lund, Sweden

Study On The Effect Of GW876008 On Cerebral Blood Flow In Irritable Bowel Syndrome (IBS) Patients And Healthy Volunteers

Phase 1

Completed

Conditions: Irritable Colon
Irritable Bowel Syndrome (IBS)

Interventions: Other: Placebo
Drug: GW876008 20mcg
Drug: GW876008 200mcg

First Posted Date: 2006-09-15

Last Posted Date: 2017-05-16

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 25

Registration Number: NCT00376896

Locations: 🇺🇸
GSK Investigational Site, Los Angeles, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy